Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med 2019; 380: 720-728.

Published: 29th April 2019

Authors: Khorana AA, Soff GA, Kakkar AK, Vadhan-Raj S, Riess H, Wun T et al.

Conclusion

Ambulatory patients at high risk of venous thromboembolism (VTE) were randomly allocated rivaroxaban for up to 180d. In the 841 patients included, rivaroxaban reduced the rate of VTE from 8.8 to 6 per cent (hazard ratio 0.66, 95 per cent confidence interval 0.4 to 1.09).

Pubmed Link

Your comments

0 Comments